Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 12, 1999, Pages 4480-4488

  Palmert, Mark R ^a,b   Mansfield, M Joan ^a   Crowley Jr , William F ^c   Crigler Jr , John F ^a   Crawford, John D ^c   Boepple, Paul A ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORELIN; GONADORELIN AGONIST; HISTRELIN;

ARTICLE; BODY COMPOSITION; BODY GROWTH; CHILD; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOGENESIS; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SKINFOLD THICKNESS;

EID: 0033305638     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.12.4480     Document Type: Article

References (55)

1. Sexual precocity
2. Precocious puberty. A report of 96 cases
3. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty
4. Gonadotrophin-releasing hormone agonist treatment of central precocious puberty: An analysis of growth data in a developmental context
5. Adult height in precocious puberty after long-term treatment with deslorelin
6. Clinical review 60: Effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty
7. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years
8. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist
9. Final height of girls with central precocious puberty, untreated vs. treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method
10. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females
11. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy
12. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone
13. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty
14. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty
15. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report
16. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty
17. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty
18. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists
19. Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche
20. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation
21. Impact of sex steroids and their suppression on skeletal growth and maturation
22. The impact of reversible gonadal sex steroid suppression on serum leptin concentrations in children with central precocious puberty
23. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion
24. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men
25. Radioimmunoassay of plasma dehydroepiandrosterone sulfate
26. Revised standards for triceps and subscapular skinfolds in British children
27. Dual-energy x-ray absorptiometry for total-body and regional bone- mineral and soft-tissue composition
28. Anthropometric reference data and prevalance of overweight, United States, 1976-1980
29. Development of normalized curves for the international growth reference: Historical and technical considerations
30. Anthropometric reference data for international use: Recommendations from a World Health Organization Expert Committee
31. Body composition during adolescence: Methods, limitations and determinants
32. DEXA supports the use of BMI as a measure of fatness in young girls
33. Cross-calibration of body-composition techniques against dual-energy x-ray absorptiometry in young children
34. The utility of body mass index as a measure of body fatness in children and adolescents: Differences by race and gender
35. Body mass index as a measure of adiposity among children and adolescents: A validation study
36. Use of the body mass index (BMI) as a measure of overweight in children and adolescents
37. Body composition of a young, multiethnic female population
38. Normative data for adrenal steroidogenesis in a healthy pediatric population: Age- and sex-related changes after adrenocorticotropin stimulation
39. Reference data for obesity: 85th and 95th percentiles of body mass index (wt/ht2) and triceps skinfold thickness
40. Guidelines for overweight in adolescent preventive services: Recommendations from an expert committee. The Expert Committee on Clinical Guidelines for Overweight in Adolescent Preventive Services
41. Predicting obesity in young adulthood from childhood and parental obesity
42. Physiological perspectives on leptin as a regulator of reproduction: Role in timing puberty
43. Sexual maturation in contemporary American girls
44. Leptin levels in children with central precocious puberty
45. Somatomedin-C in accelerated growth of children with precocious puberty
46. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist
47. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty
48. The effect of luteinizing hormone-releasing hormone analog for central precocious puberty on growth hormone (GH) and GH-binding protein
49. Alterations in growth and body composition during puberty. I. Comparing multicompartment body composition models
50. Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity
51. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty
52. Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents
53. Long-term morbidity and mortality of overweight adolescents. A follow- up of the Harvard Growth Study of 1922 to 1935